Airway Therapeutics

Airway Therapeutics is developing a protein replacement therapy to prevent and treat lung diseases in the most vulnerable patients, starting with premature infants. In addition to patent protection, the company has received orphan drug designation for AT-100 for Bronchopulmonary Dysplasia (BPD) in both the United States and the European Union, which provides incentives of 7 and 12 years of market exclusivity, respectively.